ASSOCIATION OF PATIENT AGE WITH RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR TREATMENT OF DIABETIC MACULAR EDEMA
Less improvement from baseline and greater likelihood of weak treatment response in visual acuity and central subfield thickness were observed among older patients. These findings may help refine expectations of treatment outcomes when initiating anti-vascular endothelial growth factor therapy for diabetic macular edema.
Authors
- Jennifer K. Sun (ORCID: https://orcid.org/0000-0003-0915-6303)
- Leanne T. Labriola
- Gowtham Jonna (ORCID: https://orcid.org/0009-0006-0853-6004)
- Maureen G. Maguire (ORCID: https://orcid.org/0000-0002-4249-2467)
- Danni Liu (ORCID: https://orcid.org/0000-0002-7999-716X)
- Daniel F. Martin
- Lee M. Jampol
Institutions
- Northwestern University (US)
- Joslin Diabetes Center (US)
- Weatherford College (US)
- Emory Eye Center (US)
- The Retina Center (US)
- Jaeb Center for Health Research (US)
- Clinical Research Consortium (US)
- Texas Retina Associates (United States) (US)
Publication Details
- Journal
- Retina
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1097/iae.0000000000004707
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00